The clinical implication of SS18 -SSX fusion gene in synovial sarcoma

Abstract

Background:The aim of this study is to evaluate distribution and clinical impact of the SS18-SSX fusion gene in patients with synovial sarcoma in China.Methods:We collected and analysed the clinical data of 88 patients using univariate and multivariate survival analysis. HEK 293T and NIH 3T3 cell lines were transfected with the SS18-SSX1 or SS18-SSX2 gene to determine the respective involvement of these fusion genes in cell proliferation and invasion.Results:Overall survival was significantly better among SS18-SSX2 cases (P=0.001), FNCLCC grade 2 cases (P<0.001), and UICC stage 1 or 2 (P<0.001) by univariate and multivariate survival analysis. SS18-SSX1-positive cells were more proliferative and invasive than SS18-SSX2-positive cells.Conclusion:SS18-SSX fusion type is a significant prognostic factor for patients with synovial sarcoma.

The prognostic impact of SYT‐SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials

“…The smaller the tumors the more favorable patient's outcomes. Also in previous studies smaller tumors were associated with more favorable outcome.…”

“…Some authors described histological grade G3 (FNCLCC) to be associated with adverse outcome . In the multivariate analysis of patients (4–82 years of age) by Guillou et al .…”

Metastatic synovial sarcoma of lung mimicking pulmonary embolism and deep venous thrombosis

“…It is difficult to make a definite diagnosis of SS even with histopathology. But immunohistochemistry and identification of SYT/SSX fusion transcript are useful for confirmation 6. Chemotherapy and radiotherapy are common therapy regimes for metastatic SS.…”

Synovial sarcoma diagnosis and management in the era of targeted therapies

“…In contrast, a study of 141 patients by Guillou et al [13] did not show any correlation between fusion protein status and survival. Recently, the association of SSX1 tumors with worse OS was found to be statistically significant in a Chinese study of 88 patients (P < 0.001), with additional cell line experiments showing significantly more proliferative and invasive characteristics when transfected with the SS18-SSX1 compared with the SS18-SSX2 gene [14]. Interestingly, the monophasic subtype is thought to be related to the SSX2 translocation, whereas SSX1 tumors are thought to be linked to a biphasic phenotype, implicating worse prognosis for patients with biphasic tumors [5].…”

“…In contrast to the usually early development of metastases in STS in general, a long followup study of 62 patients with synovial sarcoma reported local recurrence and metastases after a mean of 3.6 (range 0.5-15) and 5.7 years (range 0. [5][6][7][8][9][10][11][12][13][14][15][16], respectively [8].…”